FDA’s Call on Migraine Drug Could Be Trouble for Teva

Shares of Teva Pharmaceuticals weakened after
Credit Suisse downgraded the stock ahead of an FDA decision on Fremanezumab, a key migraine drug. …read more

Source:: Yahoo Finance


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.